Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX
NASDAQNVAX
FormDescriptionDateFormat
SC 13D/AAmendment to a SC 13D filingAug 26, 2004Open Amendment to a SC 13D filing in HTML.Open Amendment to a SC 13D filing in DOC file.Open Amendment to a SC 13D filing in PDF file.Open Amendment to a SC 13D filing in XLS file.
REGDEXNotification of a private placement. The form is not electronically filed with SEC EDGAR System and is available only in paper form until March 2009.Aug 4, 2004Open Notification of a private placement. The form is not electronically filed with SEC EDGAR System and is available only in paper form until March 2009. in HTML.Open Notification of a private placement. The form is not electronically filed with SEC EDGAR System and is available only in paper form until March 2009. in DOC file.Open Notification of a private placement. The form is not electronically filed with SEC EDGAR System and is available only in paper form until March 2009. in PDF file.Open Notification of a private placement. The form is not electronically filed with SEC EDGAR System and is available only in paper form until March 2009. in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 18, 2004Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.